Biotech Bull Market Intact But Speculation Is In Check Update 1
Life Science Stocks in Corrective Mode-Look for Support Today Update-winners could not hold tops with IBB ending day at $167, NASDAQ at 3321 The sector sell-off which began off the May top (up 30%) and picked up downward momentum in June is continuing today. However some large cap...
Rayno Life Science Portfolios With Sector Up 20% YTD 6/20/13
Rayno Diagnostics and Tools Portfolio Prices as of 5/29/13 Top 2013 Winners: ABAX, ALR, CSII, GHDX, ILMN, TMO, VRML Sector high was in mid-May Less volatile than biopharma but more dependent on earnings Five companies on focus list were acquired over 3 years 2010-2013 Original Price Price %...
FED No Change: Market Down 1% as Less Monetary Accommodation Likely in Future
Downside Risk to Economy Diminished So Less "Extreme Monetary Policy" In the Future? Market Stable with downward bias :S&P flat to down 18 pts-10 Year Bond Yield At 2.28% up 3.9% FED Is Optimistic about the economy: housing, consumer sentiment, financial backdrop but with fiscal drag. Bond...
Biotech Bull Market Momentum is Easing So Watch High Flyers: AEGR,CLVS etc- Update 6/16
Biotech Sell-Off Continues Nothing dramatic but the overall weakness in biopharmaceutical stocks is continuing today despite a strong performance by NASDAQ up 1.2% at 3464. With biotech having one of it best years of all time, profit taking is expected. The most popular ETFs IBB down 0.4% and...
Rayno Diagnostics and Tools Update: MYGN, SQNM Update 2 June 14
6/14 Supreme Court Ruling on Genetic Tests Takes Down Myriad Stock (MYGN $30.50)-Off Another 3% but still up 13% YTD. The Supreme Court ruling opens up competition for Myriad's breast cancer tests as well as other genetic disease markers.The immediate reaction to the stock was initially...